Correlation of MR Imaging and MR Spectroscopic Imaging Findings with Ki-67, Phospho-Akt, and Androgen Receptor Expression in Prostate Cancer
- 1 March 2009
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 250 (3), 803-812
- https://doi.org/10.1148/radiol.2503080473
Abstract
Purpose: To retrospectively assess whether magnetic resonance (MR) imaging and MR spectroscopic imaging and selected molecular markers correlate with each other and with clinically insignificant and significant prostate cancer (PCa), as defined at surgical pathologic analysis. Materials and Methods: The institutional review board approved this HIPAA-compliant study and waived informed consent. Eighty-nine men (mean age, 63 years; range, 46–79 years) with biopsy-proved PCa underwent combined endorectal MR imaging and MR spectroscopic imaging before radical prostatectomy. Suspicion of clinically insignificant PCa was retrospectively and separately recorded for MR imaging and combined MR imaging and MR spectroscopic imaging by using a scale of 0–3. Clinically insignificant PCa was pathologically defined as organ-confined cancer of 0.5 cm3 or less without poorly differentiated elements. Prostatectomy specimens underwent immunohistochemical analysis for three molecular markers: Ki-67, phospho-Akt (pAkt), and androgen receptor (AR). To examine differences in marker levels for clinically insignificant and significant cancer, a Wilcoxon rank sum test was used. To examine correlations between marker levels and MR imaging or combined MR imaging and MR spectroscopic imaging scores, the Spearman correlation was used. Results: Twenty-one (24%) patients had clinically insignificant and 68 (76%) had clinically significant PCa at surgical pathologic review. All markers were significantly correlated with MR imaging and combined MR imaging and MR spectroscopic imaging findings (all correlation coefficients >0.5). In differentiating clinically insignificant from clinically significant PCa, areas under the receiver operating characteristic curves for Ki-67, AR, pAkt, MR imaging, and combined MR imaging and MR spectroscopic imaging were 0.75, 0.78, 0.80, 0.85, and 0.91, respectively. Conclusion: The use of pretreatment MR imaging or combined MR imaging and MR spectroscopic imaging and molecular marker analyses of biopsy samples could facilitate better treatment selection. Supplemental material: http://radiology.rsnajnls.org/cgi/content/full/250/3/803/DC1 © RSNA, 2009Keywords
This publication has 62 references indexed in Scilit:
- Improved prediction of prostate cancer recurrence through systems pathologyJCI Insight, 2007
- Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imagingBJU International, 2007
- Identification of a tumour suppressor network opposing nuclear Akt functionNature, 2006
- Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy SpecimensEuropean Urology, 2005
- Molecular markers of prostate cancer outcomeEuropean Journal Of Cancer, 2005
- Imaging investigation of liver haemodynamics in patients at risk for hepatic metastatic diseaseThe British Journal of Radiology, 2005
- Organ-Confined Prostate Cancer: Effect of Prior Transrectal Biopsy on Endorectal MRI and MR Spectroscopic ImagingAmerican Journal of Roentgenology, 2004
- The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomyCancer, 2004
- Survival signalling by Akt and eIF4E in oncogenesis and cancer therapyNature, 2004
- Proton HR‐MAS spectroscopy and quantitative pathologic analysis of MRI/3D‐MRSI‐targeted postsurgical prostate tissuesMagnetic Resonance in Medicine, 2003